2018 was a fundamental year for the global microbiome market
and in particular for probiotics
. In fact, scientific research has further investigated the correlation between microbiome, bacterial mechanisms and human health
and pharma investments in the field of probiotics have grown. A clear example is the acquisition of Rebiotix by Ferring.
The current year promises to be just as important: many companies are getting the results of their phase II and III clinical trials
and there is general optimism for the sector, despite the lack of a specific regulatory orientation for the development of new products
, which we have recently discussed
. In this sense, the role of venture capital firms goes beyond the investment itself. Seventure Partners
, for example, with nearly a decade of experience with microbiome startup companies, learned how to provide them support to overcome these regulatory obstacles
We talk about it with Denise Kelly
, Professor Emeritus at the University of Aberdeen and Seventure venture partner.